HC Wainwright Reaffirms “Neutral” Rating for CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics (NASDAQ:CTMX)‘s stock had its “neutral” rating reaffirmed by HC Wainwright in a research note issued on Friday,Benzinga reports.

CytomX Therapeutics Trading Up 0.3 %

NASDAQ CTMX opened at $0.62 on Friday. CytomX Therapeutics has a 12 month low of $0.60 and a 12 month high of $5.85. The stock’s fifty day moving average price is $0.85 and its 200-day moving average price is $1.03. The stock has a market cap of $48.31 million, a P/E ratio of 3.63 and a beta of 1.01.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 EPS for the quarter, beating the consensus estimate of ($0.23) by $0.45. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. As a group, analysts forecast that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CytomX Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CTMX. Miller Financial Services LLC bought a new stake in shares of CytomX Therapeutics in the 4th quarter worth $26,000. Traphagen Investment Advisors LLC bought a new position in CytomX Therapeutics during the 4th quarter valued at about $31,000. Algert Global LLC bought a new position in CytomX Therapeutics during the 4th quarter valued at about $35,000. Velan Capital Investment Management LP purchased a new stake in shares of CytomX Therapeutics during the 4th quarter valued at about $36,000. Finally, US Bancorp DE bought a new stake in shares of CytomX Therapeutics in the third quarter worth approximately $40,000. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.